Serrapeptase vs Non-Steroidal Anti-Inflammatory Drugs
The Harmful Effects
NSAIDs, which include aspirin, ibuprofen, salicylates, ketoprofen, and naproxen, are among the most commonly prescribed medications for inflammation resulting from rheumatoid arthritis, joint conditions,
osteoarthritis, gouty arthritis, joint and muscle
discomfort associated with systemic lupus erythematosus, and other musculoskeletal disorders. (1) In some cases, this overeliance on NSAIDs has proved deadly. Annually, 76,000 people are hospitalized from
NSAID-induced gastrointestinal complications. The
American Medical Association estimates that from 50-80 percent of those hospitalized for gastrointestinal bleeding are taking some form of
NSAIDs. At this stage in the medication-induced bleeding, there is a ten percent chance of fatality. (2) This caught the FDA's attention and just
this past January, 2004 the FDA launched an awareness campaign which was established to educated consumers about the potentially lethal side effects associated with the misuse of acetaminophen and
non-steroidal anti-inflammatory drugs (NSAIDs). For more information on the FDA consumer education
campaign, visit www.fda.gov/cder/drug/analgesics/.
NSAIDs lethal effects result from the inhibition of the biosynthesis of prostaglandins. NSAIDs block cyclo-oxygenase, the enzyme responsible for catalyzing the reactions of arachidonic acid to endoperoxide compounds. This process results in the inhibition of gastric prostaglandin E, a
hormone that protects the lining of the stomach from acid. After prolonged and frequent ingestion of NSAIDs, the stomach remains defenseless and at increased susceptibility to ulcers. (3-4) If an ulcer erodes into a blood vessel, bleeding results. An ulcer can destroy part of the stomach
and duodenal walls, leaving a gap that requires immediate surgery.
In one study, 1,826 osteoarthritis or rheumatoid arthritis patients who had been taking NSAIDs for six months or more and who had been unable to tolerate continuous NSAID use because of adverse gastrointestinal symptoms were examined endoscopically for gastroduodenal lesions and ulcers.
Clinically significant gastroduodenal lesions were found in 37.1 percent of the patients. Of those, 24 percent had ulcers. The prevalence of gastroduodenal ulcers increased with age, duration of osteoarthritis, and duration of current NSAID use. The authors of the study wrote: "These
results provide further endoscopic confirmation of the association between NSAID use and gastroduodenal lesions and ulcers and support the contention that safer treatment alternatives to conventional NSAIDs are required."(5)
That advice is particularly wise in light of the other effects NSAIDs have on the gastrointestinal tract. In one group of 312 NSAID takers, 20 percent had levels of inflammation comparable to that previously reported in patients with inflammatory bowel disease. (6) Besides damaging the
gastrointestinal tract, NSAIDs also interfere with and suppress bone repair and remodeling. One paper presented data obtained over a 12-year period, and outlined the effects of NSAIDs on the matrix synthesis and turnover in 650 arthritic and 180 non-arthritic human cartilages. The study
showed that one category of NSAIDs that includes Naproxen, ibuprofen, indomethacin, and nimezulide significantly inhibited matrix synthesis and had toxic effects on cartilage metabolism. (7) Thus, it appears that the drugs many patients take to relieve their
arthritic pains actually contributes to further destruction of their joints! Additionally, NSAIDs have been shown to interfere with patients' sleep patterns. One study of 37 male and female subjects at the sleep laboratory at Bowling Green State University in Ohio demonstrated that aspirin and ibuprofen, in comparison to a placebo, increased the number of
awakenings and the percentage of time spent awake. The drugs also decreased sleep efficiency, and delayed the onset of the deeper stages of sleep. (8)
Even insulin secretion is affected by NSAIDs. Neonatal rat pancreatic cells were examined partly to determine the effects of insulin secretion caused by prostaglandin E
(PGE) and drugs that inhibit its synthesis—i.e. NSAIDs. Two NSAIDs, sodium salicylate (aspirin) and ibuprofen, at
drug concentrations similar to those achieved therapeutically in humans, inhibited PGE synthesis up to 70-80 percent. Augmented insulin secretion accompanied the PGE inhibition. Both drugs shifted the glucose-insulin response curves to the left at low glucose concentrations and augmented
maximal insulin release at high glucose concentrations. (9)
Other NSAID-induced side effects include kidney damage, blood dyscrasias and cardiovascular effects, complication of antihypertensive therapies involving diuretics or
beta-adrenoceptor blockade, and adverse effects in patients with heart failure and cirrhosis.(10) In one instance, a
woman treated for rheumatoid arthritis with the NSAID sulindac developed gallstones composed of sulindac metabolites.(11)
Interestingly, NSAIDs have also induced adverse psychiatric reactions. Five psychiatric outpatients—two with major depressive disorders, one with a bipolar disorder, one with a schizophrenic disorder and one with an anxiety disorder—were treated with NSAIDs due to rheumatoid arthritis,
osteoarthritis, or other painful neuromuscular conditions. All five patients developed moderate to severe depression. Three patients became paranoid, and four either attempted or considered suicide. These psychiatric symptoms disappeared once the patients stopped taking
NSAIDs. When the
patients re-started the drugs, the symptoms returned.(12)
Due to the detrimental effects of NSAIDs on the body, most physicians resort to a game of "NSAID musical-chairs," taking a patient off one NSAID as soon as side effects become evident or the drug stops working, then treating the patient with another of the 10 most widely
prescribed propionic acid-derived NSAIDs.
To provide a more consistent form of treatment, researchers have long searched for a side-effect free anti-inflammatory agent. Researchers have recently focused on selective cyclo-oxygenase (COX-2) inhibitors, more precise versions of NSAIDs. Whereas previous NSAIDs reduced inflammation
by inhibiting all cyclo-oxygenase activity, these new selective COX-2 inhibitors differentiate between the two forms of COX: COX-1 appears to regulate many normal physiologic functions and COX-2 mediates the inflammatory response. These selective inhibitors are believed to reduce
inflammation without influencing normal physiologic functions by inhibiting only COX-2. By leaving COX-1 alone, the selective inhibitors result in fewer gastrointestinal side effects.
At first glance, these COX-2 inhibitors look like the solution to NSAID complications. Upon further inspection, however,
celecoxib, a highly selective COX-2 inhibitor, can cause headaches, change in bowel habits, abdominal discomfort and dizziness in osteoarthritis patients. Fewer
adverse effects are reported in rheumatoid arthritis patients, but because the drug is metabolized in the liver by cytochrome P-450 isozyme CYP2C9, serious drug interactions are possible. Fung and colleagues pointed out that more clinical studies are needed before the selective COX-2
inhibitors are put into widespread use.(13)
Another new drug, Enbrel, initially showed promise of treating the pain associated with rheumatoid arthritis. Currently, however, the FDA is advising physicians about safety concerns of the new drug. Thirty of the 25,000 patients treated with Enbrel since the drug's approval
have developed serious infections, including sepsis. Several of those patients died as a result of the infections. Those at greatest risk when taking Enbrel appear to be patients with a history of chronic or recurrent infections, pre-existing infections, diabetes, or other conditions
making them more susceptible to infection.(14)
The potentially lethal side effects associated with NSAIDs and other drugs indicate that a superior anti-inflammatory substance is needed. Many healthcare practitioners have come to believe that systemic
enzymes, particularly the serrapeptase enzyme contained in World Nutrition’s Vitälzym supplement, are the best and safest alternatives to acetaminophen and
Insect-Derived Enzyme Fights Inflammation
Our bodies have a love-hate relationship with inflammation. On the one hand, inflammation is a natural response, necessary to protect the body from invading organisms. But on the other hand, inflammation can limit joint function, and destroy bone, cartilage and other particular structures.
An elusive goal of scientists and physicians has been to find a side-effect-free substance to reduce the pain and inflammation associated with fibrocystic breast disease, rheumatoid arthritis, idiopathic edema, carpal tunnel syndrome and post-operative swelling and more. It appears that
the search may be nearing an end, thanks to an enzyme Serrapeptase produced by the larval form of the silk moth.
Serrapeptase is an enzyme that is produced in the intestines of silk worms to break down cocoon walls. This enzyme is proving to be a superior alternative to the non-steroidal anti-inflammatory agents
(NSAIDs) traditionally used to treat rheumatoid arthritis and osteoarthritis.
Its uses have also been extended to the treatment of chronic sinusitis and postoperative inflammation, and some researchers believe the substance can play an important role in arterial plaque prevention and removal. Armed with the positive results
reported by Vitälzym users and in concert with the current FDA campaign, we’re pleased to help bring this message to our customers and the public.